Impact on Health-Related Quality of Life of Induction Chemotherapy Compared With Concurrent Cisplatin and Radiation Therapy in Patients With Head and Neck Cancer.


Journal

Clinical oncology (Royal College of Radiologists (Great Britain))
ISSN: 1433-2981
Titre abrégé: Clin Oncol (R Coll Radiol)
Pays: England
ID NLM: 9002902

Informations de publication

Date de publication:
09 2019
Historique:
received: 26 11 2018
revised: 12 03 2019
accepted: 12 04 2019
pubmed: 31 5 2019
medline: 14 5 2020
entrez: 1 6 2019
Statut: ppublish

Résumé

Organ preservation, an important goal in the treatment of head and neck squamous cell carcinoma (HNSCC), may include induction chemotherapy and cisplatin with radiation therapy (CRT). To our knowledge, no reports have directly compared the impact of induction chemotherapy with that of CRT on health-related quality of life (HRQOL). In a phase II trial, we assessed the HRQOL of patients treated with induction chemotherapy followed by CRT. Eligible patients had stage III-IV HNSCC. HRQOL questionnaires were administered at baseline, the end of induction (EOI), the end of CRT (EOCRT) and after CRT. Functional Assessment of Cancer Therapy (FACT version 4) assessed HRQOL. We carried out a comparison of changes in HRQOL from baseline to EOI and from EOI to EOCRT. This trial is registered with ClinicalTrials.gov (NCT01566435). Thirty patients were enrolled in the study. Most HRQOL questionnaires were completed (88%). The mean total FACT scores did not differ from baseline to EOI (general: 83.8 versus 79.1, P = 0.08; head and neck: 109.7 versus 105.8, P = 0.33; Total Outcome Index: 69.7 versus 62.3, P = 0.03; respectively, using P ≤ 0.01 to adjust for multiple simultaneous tests of differences). However, total FACT scores significantly worsened from EOI to EOCRT (79.1 versus 62.3, P = 0.01; 105.8 versus 74.2, P < 0.01; 62.3 versus 34.2, P = 0.01; respectively). Within domains, the head and neck cancer subscale score did not differ from baseline to EOI (median 28.5 versus 27.0, P = 0.69), but significantly worsened from EOI to EOCRT (27.0 versus 9.5, P < 0.01). Swallowing, oral pain and voice quality improved from baseline to EOI, but worsened from EOI to EOCRT. Physical and functional scores worsened from baseline to EOI and from EOI to EOCRT. The emotional well-being score improved from baseline to EOI but worsened from EOI to EOCRT. Overall, HRQOL did not significantly change from baseline to EOI but dramatically worsened from EOI to EOCRT.

Identifiants

pubmed: 31147146
pii: S0936-6555(19)30199-2
doi: 10.1016/j.clon.2019.05.007
pii:
doi:

Substances chimiques

Antineoplastic Agents 0
Cisplatin Q20Q21Q62J

Banques de données

ClinicalTrials.gov
['NCT01566435']

Types de publication

Clinical Trial, Phase II Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e123-e131

Informations de copyright

Copyright © 2019 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Auteurs

D Adkins (D)

Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri, USA; Division of Medical Oncology, Washington University School of Medicine, St. Louis, Missouri, USA. Electronic address: dadkins@wustl.edu.

J Ley (J)

Division of Medical Oncology, Washington University School of Medicine, St. Louis, Missouri, USA.

P Oppelt (P)

Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri, USA; Division of Medical Oncology, Washington University School of Medicine, St. Louis, Missouri, USA.

H A Gay (HA)

Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri, USA; Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri, USA.

M Daly (M)

Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri, USA; Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri, USA.

R C Paniello (RC)

Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri, USA; Department of Otolaryngology, Washington University School of Medicine, St. Louis, Missouri, USA.

R Jackson (R)

Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri, USA; Department of Otolaryngology, Washington University School of Medicine, St. Louis, Missouri, USA.

P Pipkorn (P)

Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri, USA; Department of Otolaryngology, Washington University School of Medicine, St. Louis, Missouri, USA.

J Rich (J)

Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri, USA; Department of Otolaryngology, Washington University School of Medicine, St. Louis, Missouri, USA.

J Zevallos (J)

Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri, USA; Department of Otolaryngology, Washington University School of Medicine, St. Louis, Missouri, USA.

K Trinkaus (K)

Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri, USA; Division of Biostatistics, Washington University School of Medicine, St. Louis, Missouri, USA.

W Thorstad (W)

Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri, USA; Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH